Cargando…

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations

Wee1 kinase is an inhibitor of cyclin-dependent kinase (cdk)s, crucial cell cycle progression drivers. By phosphorylating cdk1 at tyrosine 15, Wee1 inhibits activation of cyclin B-cdk1 (Cdk1), preventing cells from entering mitosis with incompletely replicated or damaged DNA. Thus, inhibiting Wee1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serpico, Angela Flavia, D’Alterio, Giuseppe, Vetrei, Cinzia, Della Monica, Rosa, Nardella, Luca, Visconti, Roberta, Grieco, Domenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627824/ https://www.ncbi.nlm.nih.gov/pubmed/31200459 http://dx.doi.org/10.3390/cancers11060819

Ejemplares similares

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Evidence that PP2A activity is dispensable for spindle assembly checkpoint-dependent control of Cdk1
por: Cervone, Nando, et al.
Publicado: (2017)

Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
por: Bi, Shuning, et al.
Publicado: (2019)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis
por: Chen, Dongshao, et al.
Publicado: (2018)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis
por: Oku, Yusuke, et al.
Publicado: (2018)

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
por: Zhou, Liang, et al.
Publicado: (2014)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
por: Bauer, Todd M., et al.
Publicado: (2023)

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
por: Hauge, Sissel, et al.
Publicado: (2019)

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
por: Kreahling, Jenny M., et al.
Publicado: (2013)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2018)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2017)

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
por: Seligmann, Jenny F., et al.
Publicado: (2021)

Fcp1 phosphatase controls Greatwall kinase to promote PP2A-B55 activation and mitotic progression
por: Della Monica, Rosa, et al.
Publicado: (2015)

Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment
por: Serpico, Angela Flavia, et al.
Publicado: (2020)

The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs
por: Visconti, R, et al.
Publicado: (2015)

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
por: Qi, Wenxiu, et al.
Publicado: (2014)

AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

Recent advances in understanding the role of Cdk1 in the Spindle Assembly Checkpoint
por: Serpico, Angela Flavia, et al.
Publicado: (2020)

AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair
por: Ford, James B., et al.
Publicado: (2015)

Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
por: Xiao, Rourou, et al.
Publicado: (2022)

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
por: Någård, Mats, et al.
Publicado: (2023)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

On the assembly of the mitotic spindle, bistability and hysteresis
por: Serpico, Angela Flavia, et al.
Publicado: (2023)

cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel
por: Serpico, Angela Flavia, et al.
Publicado: (2023)

AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells
por: Webster, Peter John, et al.
Publicado: (2017)

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
por: Lin, Xiaoting, et al.
Publicado: (2018)

Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth
por: Della Monica, Rosa, et al.
Publicado: (2023)

Mathias Mayor (1775–1847)
por: Librach, I. M.
Publicado: (1970)

Medicine in Charlestown in 1750-1775
por: Waring, Joseph Ioor
Publicado: (1935)

Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit
por: Visconti, Roberta, et al.
Publicado: (2012)

Erratum: Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit
por: Visconti, Roberta, et al.
Publicado: (2013)

Cdc25 and Wee1: analogous opposites?
por: Perry, Jennifer A, et al.
Publicado: (2007)

WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011)

Fundación Piadosa en Veracurz 1775
por: Gil, Francisco
Publicado: (1964)

Health Education From 1775 to 2005
por: Wilcox, Lynne S.
Publicado: (2005)

The Army Medical Department 1775–1818
por: Watt, Sir James
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_ej1770vp00qeuj2sg385f6u0hv